Literature DB >> 30458188

Equilin displays similar endothelium-independent vasodilator potential to 17β-estradiol regardless of lower potential to inhibit calcium entry.

Fernando P Filgueira1, Núbia S Lobato2, Denise L Nascimento3, Graziela S Ceravolo4, Fernanda R C Giachini5, Victor V Lima6, Ana Paula Dantas7, Zuleica B Fortes8, R Clinton Webb9, Rita C Tostes10, Maria Helena C Carvalho8.   

Abstract

Conjugated equine estrogens (CEE) have been widely used by women who seek to relieve symptoms of menopause. Despite evidence describing protective effects against risk factors for cardiovascular diseases by naturally occurring estrogens, little is known about the vascular effects of equilin, one of the main components of CEE and not physiologically present in women. In this regard, the present study aims to compare the vascular effects of equilin in an experimental model of hypertension with those induced by 17β-estradiol. Resistance mesenteric arteries from female spontaneously hypertensive rats (SHR) were used for recording isometric tension in a small vessel myograph. As effectively as 17β-estradiol, equilin evoked a concentration-dependent relaxation in mesenteric arteries from female SHRs contracted with KCl, U46619, PDBu or ET-1. Equilin-induced vasodilation does not involve classical estrogen receptor activation, since the estrogen receptor antagonist (ICI 182,780) failed to inhibit relaxation in U46619-precontracted mesenteric arteries. Vasorelaxation was not affected by either endothelium removal or by inhibiting the release or action of endothelium-derived factors. Incubation with L-NAME (NOS inhibitor), ODQ (guanylyl cyclase inhibitor) or KT5823 (inhibitor of protein kinase G) did not affect equilin-induced relaxation. Similarly, indomethacin (COX inhibitor) or blockage of potassium channels with tetraethylammonium, glibenclamide, 4-aminopyridine, or ouabain did not affect equilin-induced relaxation. Inhibitors of adenylyl cyclase SQ22536 or protein kinase A (KT5720) also had no effects on equilin-induced relaxation. While 17β-estradiol inhibited calcium (Ca2+) -induced contractions in high-K+ depolarization medium in a concentration-dependent manner, equilin induced a slight rightward-shift in the contractile responses to Ca2+. Comparable pattern of responses were observed in the concentration-response curves to (S)-(-)-Bay K 8644, a L-type Ca2+ channel activator. Equilin was unable to block the transitory contraction produced by caffeine-induced Ca2+ release from intracellular stores. In conclusion, equilin blocks L-type Ca2+ channels less effectively than 17β-estradiol. Despite its lower effectiveness, equilin equally relaxes resistance mesenteric arteries by blocking Ca2+ entry on smooth muscle.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  17β-Estradiol; Calcium channel; Equilin; Mesenteric arteries; Vasorelaxation

Mesh:

Substances:

Year:  2018        PMID: 30458188      PMCID: PMC6984400          DOI: 10.1016/j.steroids.2018.11.006

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  62 in total

Review 1.  Effects of estrogen on the vascular system.

Authors:  R C Tostes; D Nigro; Z B Fortes; M H C Carvalho
Journal:  Braz J Med Biol Res       Date:  2003-08-19       Impact factor: 2.590

2.  Estrogen protects against hypertension in the spontaneously hypertensive rat, but its protective mechanism is unrelated to impaired arterial muscle relaxation.

Authors:  C S Packer; N J Pelaez; J A Kramer
Journal:  J Gend Specif Med       Date:  2001

3.  Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?

Authors:  Matthias Barton; Matthias R Meyer; Elvira Haas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08       Impact factor: 8.311

4.  Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms.

Authors:  H S Leung; L M Yung; F P Leung; X Yao; Z Y Chen; W H Ko; I Laher; Y Huang
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

5.  Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism.

Authors:  G A Figtree; C M Webb; P Collins
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

6.  Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].

Authors:  Cleber E Teixeira; Fernanda B M Priviero; R Clinton Webb
Journal:  J Pharmacol Exp Ther       Date:  2005-12-13       Impact factor: 4.030

7.  Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels.

Authors:  Patcharin Tep-areenan; David A Kendall; Michael D Randall
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

8.  Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.

Authors:  A O Mueck; H Seeger; D Wallwiener
Journal:  Climacteric       Date:  2003-09       Impact factor: 3.005

9.  Endothelium-independent vasorelaxation by the selective alpha estrogen receptor agonist propyl pyrazole triol in rat aortic smooth muscle.

Authors:  José O Alda; Marta S Valero; Desiree Pereboom; Pilar Gros; Ricardo P Garay
Journal:  J Pharm Pharmacol       Date:  2009-05       Impact factor: 3.765

10.  Mechanisms of vasorelaxation to 17beta-oestradiol in rat arteries.

Authors:  Patcharin Tep-areenan; David A Kendall; Michael D Randall
Journal:  Eur J Pharmacol       Date:  2003-08-22       Impact factor: 4.432

View more
  1 in total

1.  Pharmacokinetic Study of Conjugated Equine Estrogens in Healthy Chinese Postmenopausal Women Using a Parallel Two-Column LC-MS/MS Method.

Authors:  Meiyun Shi; Lei Yin; Yantong Sun; Can Wang; Lanlan Cai; Tinglan Zhang; Xiaotong Zhou; J Paul Fawcett; Xiaoli Gao; Jingkai Gu
Journal:  Clin Pharmacokinet       Date:  2022-09-29       Impact factor: 5.577

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.